|22nd January 2021||Rita Jain||20,000||Grant/award etc.||$0.00|
|21st December 2020||Steven C Gilman||4,000||Open or private purchase||$6.25||$25,000.00|
|23rd October 2020||Scott A Canute||13,516||Sale back to the issuer||$0.00|
|1st October 2020||Steven C Gilman||7,796||Sale back to the issuer||$0.00|
|11th August 2020||Michael Thomas Heffernan||13,071||Open or private sale||$19.13||$250,048.23|
|5th August 2020||Steven C Gilman||13,000||Exercise of derivative||$10.63||$138,190.00|
|5th August 2020||Steven C Gilman||13,000||Open or private sale||$32.75||$425,750.00|
|29th July 2020||Steven C Gilman||10,000||Open or private sale||$29.70||$297,000.00|
|29th July 2020||Steven C Gilman||10,000||Exercise of derivative||$10.63||$106,300.00|
|22nd July 2020||Steven C Gilman||10,000||Grant/award etc.||$10.63||$106,300.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Akebia Therapeutics, Inc. is a biopharmaceutical company. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.